Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.370 -0.060 (-4.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,831,290
Open 1.430
Bid (Size) 1.370 (1)
Ask (Size) 1.400 (1)
Prev. Close 1.430
Today's Range 1.350 - 1.440
52wk Range 1.105 - 5.000
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire

Performance

YTD
-47.9%
-47.9%
1 Month
-44.5%
-44.5%
3 Month
-41.2%
-41.2%
6 Month
-29.4%
-29.4%
1 Year
-66.5%
-66.5%

More News

Read More
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings Scheduled For August 12, 2025
Via Benzinga
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
Via Benzinga
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Via FinancialNewsMedia
What 4 Analyst Ratings Have To Say About Autolus Therapeutics
Via Benzinga
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
Via Stocktwits
Topics Artificial Intelligence
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?
Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?
Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?
The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market
What is the current price of Autolus Therapeutics plc - American Depositary Shares?
The current price of Autolus Therapeutics plc - American Depositary Shares is 1.370
When was Autolus Therapeutics plc - American Depositary Shares last traded?
The last trade of Autolus Therapeutics plc - American Depositary Shares was at 09/09/25 04:00 PM ET
What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?
The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 71.71M
How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?
Autolus Therapeutics plc - American Depositary Shares has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.